FDA ap­proves Io­vance's cell ther­a­py for melanoma, the first treat­ment based on tu­mor-in­fil­trat­ing lym­pho­cytes

An ex­per­i­men­tal ap­proach to treat­ing can­cer more than 40 years in the mak­ing fi­nal­ly has a long-sought and re­peat­ed­ly de­layed green light from the FDA.

On Fri­day, Io­vance Bio­ther­a­peu­tics won ac­cel­er­at­ed ap­proval for Am­tagvi, a cell ther­a­py for pa­tients with ad­vanced melanoma. It’s the first mod­ern cell ther­a­py for a sol­id tu­mor, rather than blood can­cer, and the first ap­proved treat­ment based on tu­mor-in­fil­trat­ing lym­pho­cytes, or TILs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER